Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
03/2003
03/06/2003WO2003018057A1 Remedy for glaucoma comprising as the active ingredient compound having pi3 kinase inhibitory effect
03/06/2003WO2003018047A2 Hdl for the treatment of stroke and other ischemic conditions
03/06/2003WO2003018044A1 New drug
03/06/2003WO2003018038A2 Composition for the treatment of varicose veins
03/06/2003WO2003018024A1 Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
03/06/2003WO2003018020A1 Jnk inhibitors
03/06/2003WO2003018016A1 Use of moxaverin for treating erectile dysfunction, forms of dementia or diseases associated to an arteriosclerotic occlusion
03/06/2003WO2003018010A1 Preventive and/or remedial agent for disease attributable to arteriosclerotic activity
03/06/2003WO2003018008A1 Apo ai expression accelerating agent
03/06/2003WO2003018001A1 Apolipo protein e secretion promoters
03/06/2003WO2003017994A1 Amidine derivatives for treating amyloidosis
03/06/2003WO2003017992A2 Means for treatment of atherosclerosis
03/06/2003WO2003017991A2 Injection solution containing a dihydropyridin derivative
03/06/2003WO2003017989A1 Compositions and techniques for localized therapy of restenosis
03/06/2003WO2003017983A1 A new extended release oral dosage form
03/06/2003WO2003017982A1 A new extended release oral dosage form
03/06/2003WO2003017949A2 Novel synthetic ganglioside derivatives and compositions thereof
03/06/2003WO2003017946A2 Non-oxidatively metabolized compounds and compositions, synthetic pathways therefor, and uses thereof
03/06/2003WO2003017939A2 Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment
03/06/2003WO2003017919A2 Composition comprising wenguanguo extracts, methods for preparing same and uses therof
03/06/2003WO2003000240A3 Stable powder inhalation dosage formulation
03/06/2003WO2002102381A9 Acylic piperazine and piperidine derivatives which are useful for treating neuronal damage
03/06/2003WO2002096367A3 Targeted multivalent macromolecules
03/06/2003WO2002095026A8 Method of proliferating terminal differentiated cells and recombinant vector therefor
03/06/2003WO2002092122A3 Use of osteopontin for the treatment and/or prevention of neurologic diseases
03/06/2003WO2002086069A3 Secreted proteins
03/06/2003WO2002085376A3 A method for decreasing superoxide anion production and for the treatment of diseases associated with oxidative stress
03/06/2003WO2002083066A3 Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
03/06/2003WO2002074249A3 Pharmaceuticals and methods for treating hypoxia and screening methods therefor
03/06/2003WO2002072570A3 Non-imidazole compounds as histamine h3 antagonists
03/06/2003WO2002066516A3 Antibodies that bind both bcma and taci
03/06/2003WO2002066443A3 2-thioxo-1,2,3,4-tetrahydropyrimidine derivatives
03/06/2003WO2002064210A3 Combination therapy comprising anti-diabetic and anticonvulsant agents
03/06/2003WO2002063961B1 Composition and methods for modulation of vascular structure and/or function
03/06/2003WO2002060929A3 Polymer conjugates of neublastin and methods of using same
03/06/2003WO2002060387A3 Use of prostaglandin analogs for treatment of cardiac conditions
03/06/2003WO2002059302A3 Regulation of human serotonin-like g protein-coupled receptor
03/06/2003WO2002058625A3 Herbal composition for angina pectoris, method to prepare same and uses thereof
03/06/2003WO2002056837A3 Inhibition of protein-phosphatases for the treatment of heart failure
03/06/2003WO2002051383A3 Controlled release of anti-arrhythmic agents from a biodegradable polyethylene oxide hydrogel for local application to the heart
03/06/2003WO2002034726A9 Pyrimidine-2,4,6-trione metalloproteinase inhibitors
03/06/2003WO2002028376A3 Chrono delivery formulations and method of use thereof
03/06/2003WO2002026947A3 Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
03/06/2003WO2002024672A3 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases
03/06/2003WO2002022801A3 Mammalian receptor genes and uses
03/06/2003WO2002020516A1 Novel crystals of 1,3,4-oxadiazole derivative, process for producing the crystals and medicines containing the same as the active ingredient
03/06/2003WO2002009714A9 Compositions and methods for the treatment of anorectal disorders
03/06/2003WO2001098361A9 Agonist anti-trk-c monoclonal antibodies
03/06/2003WO2001092304A3 Transporters and ion channels
03/06/2003WO2001089483A9 Tablets and methods for modified release of hydrophilic and other active agents
03/06/2003WO2001077146A3 Compounds and methods for modulating endothelial cell adhesion
03/06/2003WO2001074900A9 Nuclear factor kb inducing factor
03/06/2003US20030046718 Administering compounds having an effect on cardiac fibrosis, myocardial infarction, defects in electrical conductance, atherosclerosis, unstable plaque, and stroke in an animal which does not express an active SR-BI, and an apolipoprotein
03/06/2003US20030045865 Compositions and techniques for localized therapy
03/06/2003US20030045744 Preparing the chemical intermediate of perindopril, by reacting sodium pyruvate with a salt of norvalinates, catalyzing the hydrogenation in presence of palladium on carbon, acidification, filtration
03/06/2003US20030045728 Indol-3-yl derivatives
03/06/2003US20030045718 Crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid
03/06/2003US20030045686 Mutein polypeptide for use in the treatment of hypoxia and ischemic related tissue damages
03/06/2003US20030045586 Use of amines
03/06/2003US20030045574 Such as alpha-phenyl-N-(7-tert-butoxycarbonylamino-3,5-dimethyladamantane)nitrone for treatment of neurological/ inflammatory diorders, and aging, which result from the overproduction of nitric oxide
03/06/2003US20030045565 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
03/06/2003US20030045560 6-(Aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
03/06/2003US20030045558 Such as 2-(4-(2-(2-(4-(3,5-dimethyl-isoxazol-4-yl)-phenyl)-5-methyloxazol-4-yl) -ethyoxy)-phenoxy)-2-methylpropionic acid for treatment of diabetes (lowering serum triglycerides)
03/06/2003US20030045554 Such as 1-(2-thien-2'-yl- 2-oxoethyl)-3-((3-phenylmethyl) pyrazol-5-yl)pyridinium bromide for treating diseases caused by the accumulation of AGE (Advanced Glycation Endproducts); antidiabetic/ antiaging agents
03/06/2003US20030045552 Isoindole-imide compounds, compositions, and uses thereof
03/06/2003US20030045535 Antiproliferative and antitumor agents
03/06/2003US20030045533 Phosphodiesterase 4 inhibitors
03/06/2003US20030045530 Administering a piperazine or piperidine coupled through a linker to a benzhydril
03/06/2003US20030045529 Method for specifically potentiating N-type Ca2+ channel activity
03/06/2003US20030045522 Novel galenical form for oral administration with prolonged release of molsidomine
03/06/2003US20030045521 Sulfohydroxamic acids and sulfohydroxamates and their use as MEK inhibitors
03/06/2003US20030045519 Treating allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion)
03/06/2003US20030045517 Nonpeptide substituted spirobenzoazepines as vasopressin antagonists
03/06/2003US20030045516 Chemokine receptor antagonists and methods of use therefor
03/06/2003US20030045515 Cyanoguanidine I kappa B kinase inhibitors as antiproliferative agents for cancer treatment
03/06/2003US20030045490 Therapeutic antisense phosphodiesterase inhibitors
03/06/2003US20030045478 Treating diseases such as cardiac and cerebral ischemia or reperfusion injury, sepsis and bacterial meningitis.
03/06/2003US20030045476 Heart homing conjugates
03/06/2003US20030045469 Treatment of congestive heart failure
03/06/2003US20030045460 Orally administered peptides to ameliorate atherosclerosis
03/06/2003US20030045449 Pharmaceutical combinations for the treatment of neurodegenerative diseases
03/06/2003US20030044898 Nucleotide sequences coding polypeptide for use in the treatment of asthma, parkinson's, heart defects, hypotension, urogenital and bone disorders
03/06/2003US20030044893 Nectin polypeptides, polynucleotides, methods of making and use thereof
03/06/2003US20030044810 Methods, compositions, and kits relating to cardiovascular disease
03/06/2003US20030044514 Using supercritical fluids to infuse therapeutic on a medical device
03/06/2003US20030044464 Sustained-release, oral pharamaceutical forms of formulation
03/06/2003US20030044446 A multilayered film comprising a first, water-soluble adhesive layer to be placed in contact with a mucosal surface and a second, water-erodible non-adhesive backing layer that controls residence time; drug delivery from mouth
03/06/2003US20030044390 Applying stresses to blood sampling
03/06/2003US20030044385 Antitumor, anticancer agents
03/06/2003CA2465676A1 Compositions and techniques for localized therapy of restenosis
03/06/2003CA2458622A1 Copper-dependent non-traditional pro-inflammatory cytokine export and methods, compositions and kits relating thereto
03/06/2003CA2458621A1 Oral antidiabetic agents
03/06/2003CA2458574A1 Reagents and methods for smooth muscle therapies
03/06/2003CA2458565A1 New angiogenesis inhibitors based on soluble cd44 receptor hyaluronic acid binding domain
03/06/2003CA2458443A1 Bioadhesive compositions and methods for enhanced mucosal drug absorption
03/06/2003CA2458371A1 Glucagon-like peptide-1 analogs
03/06/2003CA2458131A1 Jnk activation inhibitor
03/06/2003CA2457976A1 Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
03/06/2003CA2457974A1 Combination preparations of aryl substituted propanolamine derivatives with other active ingredients and the use thereof
03/06/2003CA2457846A1 Use of heparinoid derivatives for treating and diagnosing diseases that can be treated by heparinoids
1 ... 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 1050 1051 1052 1053 1054 1055 1056 ... 1595